Two People Disease-Free 15 Years After Stem Cell Treatment

Imagine being unable to see clearly, losing feeling in your limbs, and facing a disease with no cure. That was reality for two people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition where the immune system attacks the spinal cord and optic nerve. Today, more than 15 years after an experimental treatment, both are living proof that medical breakthroughs can change lives forever.

The man received stem cells from his sister in 2009. The woman followed a year later with cells from an unrelated donor. Before the transplant, both patients received chemotherapy to wipe out the harmful immune cells causing their symptoms.

The results stunned researchers. The man's neurological function improved so much that he returned to normal life and became a father to two children. The woman regained the ability to use her arms effectively and no longer needs medication to control her symptoms.

Dr. Massimo Filippi and his team at IRCCS San Raffaele Hospital in Milan made history with this treatment. They're the first to use this type of stem cell transplant for NMOSD. The procedure replaces the entire immune system with healthy donor cells, eliminating the antibodies that were attacking the nervous system.

Before this treatment, both patients had tried standard medications without success. Their episodes included severe eye pain, vision loss, weakness, and paralysis. Current treatments can prevent episodes but require lifelong medication and don't work for everyone.

The transplant comes with serious risks. Both participants experienced side effects, and developing infections or secondary cancers after stem cell treatment isn't uncommon. The team emphasizes this procedure should only be considered for young patients who don't respond to standard care.

The Ripple Effect

This 15-year success story is opening doors for others facing similar challenges. Bruce Milthorpe, a scientist at the University of Technology Sydney, calls the long-term symptom-free results exciting and believes this study provides strong evidence for launching larger clinical trials.

The method used to collect stem cells directly from blood rather than bone marrow is another win. It's less invasive and could make the procedure more accessible to future patients. While finding suitable donors remains challenging, the possibility of long-term remission offers new hope.

Biomedical engineer Jiao Jiao Li notes that while calling it a cure might be premature, the treatment has addressed the disease's impact over an incredibly long time. Neither patient developed the antibodies associated with NMOSD, and both built healthy immune systems.

For people with severe autoimmune diseases that don't respond to medication, this research represents more than scientific progress—it's a glimpse of a future where devastating conditions might become manageable.